Efficacy of maintenance therapy with rituximab after induction chemotherapy (R-CHOP [cyclophosphamide + doxorubicin + vincristine + prednisone + rituximab] Vs. R-FC [fludarabine + cyclophosphamide + rituximab]) for elderly patients with mantle cell lymphoma not suitable for autologous stem cell transplantation.

Trial Profile

Efficacy of maintenance therapy with rituximab after induction chemotherapy (R-CHOP [cyclophosphamide + doxorubicin + vincristine + prednisone + rituximab] Vs. R-FC [fludarabine + cyclophosphamide + rituximab]) for elderly patients with mantle cell lymphoma not suitable for autologous stem cell transplantation.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Mar 2017

At a glance

  • Drugs Rituximab (Primary) ; Cyclophosphamide; Doxorubicin; Fludarabine; Interferon alpha-2a; Peginterferon alfa-2b; Prednisone; Vincristine
  • Indications Mantle-cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Mar 2017 Planned End Date changed from 1 Dec 2014 to 1 Dec 2018.
    • 06 Mar 2017 Planned primary completion date changed from 1 Dec 2014 to 1 Dec 2018.
    • 06 Sep 2012 Planned end date changed from 1 Jan 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top